These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37473963)

  • 21. Reverse genetics systems for SARS-CoV-2.
    Wang W; Peng X; Jin Y; Pan JA; Guo D
    J Med Virol; 2022 Jul; 94(7):3017-3031. PubMed ID: 35324008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery.
    Ge F; Xiong S; Lin FS; Zhang ZP; Zhang XE
    Antiviral Res; 2008 Nov; 80(2):107-13. PubMed ID: 18584889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel cell culture system modeling the SARS-CoV-2 life cycle.
    Ju X; Zhu Y; Wang Y; Li J; Zhang J; Gong M; Ren W; Li S; Zhong J; Zhang L; Zhang QC; Zhang R; Ding Q
    PLoS Pathog; 2021 Mar; 17(3):e1009439. PubMed ID: 33711082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reverse genetic systems of SARS-CoV-2 for antiviral research.
    Kurhade C; Xie X; Shi PY
    Antiviral Res; 2023 Feb; 210():105486. PubMed ID: 36657881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
    Zhang X; Liu Y; Liu J; Bailey AL; Plante KS; Plante JA; Zou J; Xia H; Bopp NE; Aguilar PV; Ren P; Menachery VD; Diamond MS; Weaver SC; Xie X; Shi PY
    Cell; 2021 Apr; 184(8):2229-2238.e13. PubMed ID: 33691138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the 3' cis-acting elements of rubella virus by using replicons expressing a puromycin resistance gene.
    Chen MH; Frolov I; Icenogle J; Frey TK
    J Virol; 2004 Mar; 78(5):2553-61. PubMed ID: 14963158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of A MERS-CoV Replicon Cell Line for Antiviral Screening.
    Chen J; Hu BJ; Zhao K; Luo Y; Lin HF; Shi ZL
    Virol Sin; 2021 Aug; 36(4):730-735. PubMed ID: 33616893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon.
    Li N; Chen XL; Li Q; Zhang ZR; Deng CL; Zhang B; Li XD; Ye HQ
    Emerg Microbes Infect; 2022 Dec; 11(1):465-476. PubMed ID: 35034586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of a Rapid Detection System for ISG20-Dependent SARS-CoV-2 Subreplicon RNA Degradation Induced by Interferon-α.
    Furutani Y; Toguchi M; Higuchi S; Yanaka K; Gailhouste L; Qin XY; Masaki T; Ochi S; Matsuura T
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA.
    Hertzig T; Scandella E; Schelle B; Ziebuhr J; Siddell SG; Ludewig B; Thiel V
    J Gen Virol; 2004 Jun; 85(Pt 6):1717-1725. PubMed ID: 15166457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of Vero cell lines persistently harboring a yellow fever virus 17D subgenomic replicon.
    Saito K; Shimasaki K; Fukasawa M; Suzuki R; Okemoto-Nakamura Y; Katoh K; Takasaki T; Hanada K
    Virus Res; 2022 Dec; 322():198935. PubMed ID: 36152929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment and Application of Flavivirus Replicons.
    Kümmerer BM
    Adv Exp Med Biol; 2018; 1062():165-173. PubMed ID: 29845532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
    Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
    Elife; 2021 Oct; 10():. PubMed ID: 34617885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.
    Fernandes RS; Freire MCLC; Bueno RV; Godoy AS; Gil LHVG; Oliva G
    Viruses; 2020 May; 12(6):. PubMed ID: 32486283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral replicons as valuable tools for drug discovery.
    Hannemann H
    Drug Discov Today; 2020 Jun; 25(6):1026-1033. PubMed ID: 32272194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
    Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
    Front Immunol; 2022; 13():811802. PubMed ID: 35250985
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.